0000899243-21-025984.txt : 20210625
0000899243-21-025984.hdr.sgml : 20210625
20210625170046
ACCESSION NUMBER: 0000899243-21-025984
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210412
FILED AS OF DATE: 20210625
DATE AS OF CHANGE: 20210625
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wallace Owen B.
CENTRAL INDEX KEY: 0001778843
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40522
FILM NUMBER: 211048791
MAIL ADDRESS:
STREET 1: C/O FULCRUM THERAPEUTICS, INC.
STREET 2: 26 LANDSDOWNE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Monte Rosa Therapeutics, Inc.
CENTRAL INDEX KEY: 0001826457
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 645 SUMMER STREET
STREET 2: SUITE 102
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 617-949-2643
MAIL ADDRESS:
STREET 1: 645 SUMMER STREET
STREET 2: SUITE 102
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-04-12
0
0001826457
Monte Rosa Therapeutics, Inc.
GLUE
0001778843
Wallace Owen B.
MONTE ROSA THERAPEUTICS, INC.
645 SUMMER STREET, SUITE 102
BOSTON
MA
02210
0
1
0
0
Chief Scientific Officer
Stock Option (Right to Buy)
6.14
2021-04-12
4
A
0
387069
0.00
A
2031-04-12
Common Stock
387069
387069
D
Stock Option (Right to Buy)
19.00
2021-06-23
4
A
0
113298
0.00
A
2031-06-22
Common Stock
113298
113298
D
On June 17, 2021, the Issuer completed a one-for-3.5305 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split.
This transaction occurred prior to the Issuer's initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The securities covered by such transaction were previously included on the Reporting Person's Form 3.
25% of this option shall vest and become exercisable on February 8, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.
25% of this option shall vest and become exercisable on May 28, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.
/s/ Ajim Tamboli, Attorney-in-Fact
2021-06-25